Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Community-acquired pneumonia in adults

D Y Sue1

  • 1Department of Medicine, Harbor-UCLA Medical Center, Torrance 90509-2910.

The Western Journal of Medicine
|October 1, 1994
PubMed
Summary

Community-acquired pneumonia (CAP) has diverse causes, including Streptococcus pneumoniae and atypical pathogens. Empiric macrolide antibiotics offer broad coverage for non-immunocompromised patients with CAP.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Underdiagnosis of airway obstruction in older people--be careful what you look for, you might find it.

Journal of the American Geriatrics Society·2001
Same author

Exertional dyspnea in congestive heart failure. Living longer and doing more?

Chest·2000
Same author

Differences between remaining ability and loss of capacity in maximum aerobic impairment.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·1998
Same author

Obesity and pulmonary function: more or less?

Chest·1997
Same author

Inaccuracy of noninvasive estimates of VD/VT in clinical exercise testing.

Chest·1994
Same author

Exercise testing in the evaluation of impairment and disability.

Clinics in chest medicine·1994

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology

Background:

  • Community-acquired pneumonia (CAP) remains a significant public health concern with high morbidity and mortality, particularly in vulnerable populations.
  • While Streptococcus pneumoniae is a common cause of CAP, atypical pathogens like Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila account for 20-40% of adult cases.
  • Clinical differentiation between typical and atypical pneumonia is often challenging, making empiric treatment strategies crucial.

Purpose of the Study:

  • To review the spectrum of etiologic agents responsible for CAP.
  • To evaluate the clinical utility of differentiating between typical and atypical pneumonia.
  • To discuss appropriate empiric antimicrobial therapy selection for CAP management.

Main Methods:

  • Literature review and synthesis of existing studies on CAP epidemiology and treatment.
  • Analysis of clinical presentation and diagnostic challenges associated with various pneumonia pathogens.
  • Evaluation of antimicrobial efficacy and spectrum of activity for empiric CAP therapy.

Main Results:

  • A significant proportion of CAP cases (20-40%) are caused by atypical pathogens, often presenting indistinguishably from S pneumoniae infections.
  • Failure to identify an etiologic agent occurs in 35-50% of CAP patients.
  • Macrolide antibiotics (e.g., erythromycin) demonstrate broad-spectrum activity against common CAP pathogens, including S pneumoniae, M pneumoniae, and L pneumophila, with some efficacy against C pneumoniae.

Conclusions:

  • The distinction between typical and atypical pneumonia is clinically unhelpful for initial therapeutic planning.
  • Empiric antimicrobial therapy should consider the likelihood of various pathogens, with macrolides being a valuable option for non-immunocompromised hosts.
  • Treatment should be tailored based on patient factors, clinical suspicion, and diagnostic findings when available.

Related Experiment Videos